Fill-finish 의약품 수탁제조 시장 : 제품별, 분자별, 최종 용도별, 세계 예측(2024-2032년)

Fill-finish pharmaceutical contract manufacturing market size will depict 6.2% CAGR from 2024 to 2032, driven by the increasing outsourcing trend among pharmaceutical companies to streamline production processes and reduce operational costs. For instance, in March 2024, SMC Ltd. acquired a fill/finish facility in Charlotte, NC, for expanding services to pharma clients with lab-to-market development, device manufacture, and secondary packaging.

Contract manufacturers equipped with advanced technologies and facilities are ensuring adherence to stringent quality standards and compliance with regulatory guidelines, including Good Manufacturing Practices (GMP). This capability is also essential for meeting the increasing global demand for high-quality pharmaceutical products while navigating the complexities of international markets.

The overall industry is segmented into product, molecule, end-use and region.

Based on product, the fill-finish pharmaceutical contract manufacturing market from the prefilled syringes segment is set to grow up to 2032 due to the increasing demand for convenient and safe drug delivery systems. Prefilled syringes offer advantages, such as precise dosage delivery, reduced risk of contamination, and ease of administration, making them popular among healthcare providers and patients. Contract manufacturers specializing in fill-finish services also help in meeting these demands by providing expertise in sterile filling, assembly, and packaging of prefilled syringes.

With respect to end use, the fill-finish pharmaceutical contract manufacturing market from the pharmaceutical companies segment will record a notable growth rate between 2024 and 2032 favored by outsourcing to enhance operational efficiency and focus on core competencies. Pharmaceutical firms are increasingly relying on CMOs for fill-finish services to streamline production, reduce time-to-market, and manage costs effectively. Contract manufacturing further offers pharmaceutical companies access to specialized expertise in sterile filling, packaging, and regulatory compliance, favoring the segment growth.

Asia Pacific fill-finish pharmaceutical contract manufacturing industry size is anticipated to grow at an impressive pace through 2032 fueled by increasing healthcare expenditure, growing population, and the rising prevalence of chronic diseases. The strategic geographical location and infrastructure improvements are facilitating easier access to key global markets for enhancing the competitiveness on international stage. Pharmaceutical companies are also continuing to expand their operations and invest in innovative drug formulations, subsequently stimulating the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing trend of pharmaceutical outsourcing
    • 3.2.1.2 Rising technological advancements in fill-finish manufacturing processes
    • 3.2.1.3 Increasing complexity of drug formulations
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory issues
    • 3.2.2.2 Competition from in-house manufacturing
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Vials
  • 5.2.1 Glass vials
  • 5.2.2 Plastic vials
• 5.3 Prefilled syringes (PFS)
  • 5.3.1 Glass PFS
  • 5.3.2 Plastic PFS
• 5.4 Cartridges
• 5.5 Other products

Chapter 6 Market Estimates and Forecast, By Molecule, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Large molecules
• 6.3 Small molecules

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Biopharmaceutical companies
• 7.3 Pharmaceutical companies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Boehringer Ingelheim International GmbH
• 9.2 Catalent Inc.
• 9.3 Eurofins Scientific
• 9.4 Fresenius Kabi Contract Manufacturing
• 9.5 MabPlex International Co. Ltd.
• 9.6 Novartis AG
• 9.7 Recipharm AB
• 9.8 Societal CDMO
• 9.9 Simtra BioPharma Solutions (Baxter International Inc.)
• 9.10 Symbiosis Pharmaceutical Services